ライフサイエンスコーパス: GTT

1 elomeric oligonucleotide 5'-d[AGGGTTAG(8)G(9)GTT AG(14)G(15)GTTAGGGTGT]-3'.

2 ch nondiabetic control subjects were given a GTT.

3 elective antagonist to WT mice resulted in a GTT profile that mirrored that of Ucn 2-null mice.

4 > CCA at amino acid 576, and the other was a GTT deletion at amino acid 560.

5 All GTT subtypes express programmed death-ligand 1 (PD-L1),

6 iedreich ataxia, as well as for ATT, CCT and GTT repeats.

7 predictor of mortality in both diabetes and GTT population samples.

8 tains four loops: three lateral (TT, TT, and GTT) and one propeller (TT).

9 triplet repeat sequences (GTA.TAC, GAT.ATC, GTT.AAC, CAC.GTG, AGG.CCT, TCG.CGA, and AAG.CTT), and th

10 subunit; H156Y-beta (CAT to TAT), V69G-beta (GTT to GGT), IVS 9 del[-7:-4], and 1109 ins 8bp (exon 10

11 bi from native blood using the point-of-care GTT can identify ACS patients at risk of future cardiac

12 d glucose and slowed glucose disposal during GTTs.

13 d variants were determined to contain either GTT or TGACTGTT sequence, in lieu of 20,214 or 18,895 bp

14 r sequential or combination chemotherapy for GTT.

15 No deaths from GTT have occurred later than 2 years after the end [corr

16 -binding site (MBS) sequence (YG(A/G)C(A/C/G)GTT(G/A)).

17 d the Myb-binding site (MBS) [YG(A/G)C(A/C/G)GTT(G/A)].

18 a-inhibitory aptamer oligonucleotide, 5'-GGG GTT GGT TGT GTT GGG TGT TGT GT, as a model system.

19 Oligonucleotide 5'-GGG GTT GGT TGT GTT GGG TGT TGT GT-RNH2 (oligo I) blocks mul

20 ' splice site mutation in intron 24, GGT --> GTT (maternal allele), and a new 3' splice site mutation

21 TT) before pregnancy, significantly impaired GTT and remarkably higher serum glucose concentrations i

22 Epm2b-/- mice also showed no differences in GTTs and ITTs.

23 by action of ppGaNTase-T1 on MUC5AC (mainly GTT(GalNAc)PSPVPTTSTT(GalNAc)SAP), additional incorporat

24 Neither TTG nor GTT start codons, inferred for several genes of other ne

25 increased insulin area under curve (AUC) on GTT compared with MTPa+/+ littermates.

26 raperitoneal glucose tolerance (ipGTT), oral GTT or mixed meal substrate control, including postprand

27 were noted on other clinical parameters (PD, GTT, KG, GI, and PI).

28 For reducing GTT, Among the included studies, erythromycin and magnet

29 ast to Pot1pN, tandem trinucleotide repeats (GTT) within d(GGTTACGGTTAC) are specifically recognized

30 nts with single-agent chemotherapy-resistant GTT, avelumab had a favorable safety profile and cured a

31 velumab in women with chemotherapy-resistant GTT.

32 ly toxic regimen for patients with high-risk GTT who become refractory to or relapse from EMA/CO chem

33 otal of 272 consecutive women with high-risk GTT, including 121 previously treated patients, were tre

34 ive and well-tolerated regimen for high-risk GTT.

35 onths led to similar weight gain and similar GTT and ITT responses.

36 We used the global thrombosis test (GTT) to assess thrombotic and thrombolytic status in 300

37 p strength, rotarod, glucose tolerance test (GTT) and insulin tolerance test (ITT), body composition,

38 was evaluated using glucose tolerance test (GTT) and insulin tolerance test (ITT).

39 ucose clearance in a glucose tolerance test (GTT) and normalization of liver glycogen levels.

40 trast to an improved glucose tolerance test (GTT) before pregnancy, significantly impaired GTT and re

41 Glucose tolerance test (GTT), insulin tolerance test (ITT), fasting blood glucos

42 g an intraperitoneal glucose tolerance test (GTT).

43 (PP), an intravenous glucose-tolerance-test (GTT) and AT biopsies were performed.

44 ype 2 diabetes and glucose-tolerance-tested (GTT) multiethnic population samples.

45 n sensitivity using glucose tolerance tests (GTTs) and hyperinsulinemic-euglycemic clamps in mouse mo

46 d no differences in glucose tolerance tests (GTTs) or insulin tolerance tests (ITTs) compared with wi

47 Using glucose-tolerance tests (GTTs), insulin-tolerance tests (ITTs), and hyperinsuline

48 aptamer oligonucleotide, 5'-GGG GTT GGT TGT GTT GGG TGT TGT GT, as a model system.

49 Oligonucleotide 5'-GGG GTT GGT TGT GTT GGG TGT TGT GT-RNH2 (oligo I) blocks multiple IFN-ga

50 multiple folding and unfolding events of the GTT WW domain, a small protein often used as a model for

51 CHCl3@3, and CHCl3@4 complexes, whereas the GTT conformation was found the most favorable for the CH

52 of synthetic Ucn 2 to mutant mice before the GTTs and ITTs restored blood glucose to WT levels.

53 ed blood flow, granulation tissue thickness (GTT), and CD31 that correlated with increased BTG2 expre

54 obing depth (PD), gingival tissue thickness (GTT), and width of keratinized gingiva (KG) were assesse

55 Primary outcomes were gastric transit time (GTT), small bowel transit time (SBTT), and completion ra

56 from the same patient (at codon 525; ATT to GTT, isoleucine to valine).

57 Applying the same protocol to GTT, NTL9, and protein G suggests that some beta contain

58 Women with gestational trophoblastic tumors (GTT) resistant to single-agent chemotherapy receive alte

59 herapy for gestational trophoblastic tumors (GTT).

60 The survival for patients with GTT is 30 (88%) out of 34 patients and four (50%) out of

61 als.gov identifier: NCT03135769), women with GTT who experienced disease progression after single-age